How will Mid-plex proteomics enhance your research?
Problem
When research findings need to be validated, a robust and well-proven technology with fast turnaround time is needed.
Solution
Luminex(™) has become the world leader in mid-plex technologies for more than two decades with more than 1300 commercially available panels and almost 60,000 peer-reviewed publications. Incorporate mid-plex analysis into your research methodology to validate your novel biological insights.
What is Mid-plex Protein Analysis
Mid-Plex Protein Analysis refers to the simultaneous analysis of 10s of proteins providing a robust understanding of the protein landscape. Rely on Protavio’s validated Mid-Plex panels or choose from >1300 pre-made panels and analyse your samples in less than a week’s time. Choose your panels of interests and validate important biological mechanisms.
73x Human-Cyto-Plex: A comprehensive panel of well-know Human cytokines to validate your findings and secretion patterns in cells, biological fluids, and solid tissues
20x Path-Plex: A comprehensive panel of well-known intracellular phosphoproteins to understand the signaling events in cells, fluids, and tissues. Applicable for human, rat, and mice sample
36x Rat-Plex: A comprehensive panel of well-know Rat cytokines to validate your findings and secretion patterns
45x Mouse-Plex: A comprehensive panel of well-know Mouse cytokines to validate your in-vivo findings
1300+ additional panels: Are you interested in Bovine, Feline, Chicken, Canine, Equine, Non-Human Primate, Murine, Ovine, Porcine, Plant, Primate or other species?
Contact us to select your pre-made panels of interest and validate your biological hypothesis.
Why rely on a Mid-Plex protein analysis?
Orthogonal Biomarker Validation:
Orthogonally validate your screening results (i.e. Olink, Somalogic, Mass Spec) and get a piece of mind that your screening findings are not just a cross-reactivity artifact.
Robust Biological Insights:
Validate your biological findings with a well-established, proven technology and fast turnaround times.
Cost-Effectiveness and Fast Turnaround Times:
Rely on 1300+ pre-made panels that cover all major biological pathways and receive your results in a week.
Drug Development and Validation:
Validate if your proteins of interest are affected by drugs, perturbations, and compounds of interest.
Personalized Medicine:
Profile individual patients’ protein expression patterns that guide treatment decisions and predict responses to specific interventions.
Publication Impact:
Mid-Plex studies often generate comprehensive datasets that can lead to impactful publications, advancing the field and contributing to scientific knowledge.
How we work
Design the study
Instead of just analyzing your samples, we provide you with a dedicated proteomic specialist who possesses extensive knowledge and ensures that the study design is tailored to your specific requirements and hypothesis.
Send samples
Send your samples to either our European or US dedicated sample collection sites, equipped with state-of-the-art storage infrastructure and monitoring. You can use either our approved carriers or follow your own shipment processes.
Receive report
Obtain a comprehensive proteomic analysis report encompassing the study design, detailed methodology, dataset, visualizations, bioinformatic analysis, and any additional agreed-upon services outlined in the study plan.
Receive consultation
Schedule a one-hour consultation call with our Chief Scientific Officer and our Project Manager to discuss crucial biological discoveries and address any further inquiries you may have for advancing your research to the next level.
Orthogonal biomarker validation with multiple platforms
The Team
Leonidas Alexopoulos
PhD, Acting CEO, Professor, National Technical University of Athens
Leonidas is one of the pioneers of multiplex assays & systems biology with more than 20 years of experience in the field of proteomics. He has studied at Duke, MIT and Harvard and is currently a professor at National Technical University of Athens. Leonidas co-founded Protavio in 2011 with the ultimate goal of improving people’s health through innovation in proteomics.
Sophia Stamatatou
Co-founder, COO & Quality Director, MSc, MBA
Sophia holds an MSc in Robotics & Automation and an MBA from National Technical University of Athens. Her passion for engineering and entrepreneurship led her to co-found Protavio in 2011. Since 2018, she has held the position of Chief Operating Officer and Quality Director. Her decade long experience of business development and administration make her a key decision maker in Protavio.
Nikos Tsolakos
Chief Scientific Officer, Phd
Nikos holds a PhD from Imperial College London and has over 15 years of work experience in academic and industrial research positions in the field of proteomics. Nikos joined Protavio in 2017 as a Quality Assurance & Project Manager. Since 2023, he holds the position of Chief Scientific Officer to advance Protavio’s proteomic solutions.
Christos Fotis
Chief Innovation Officer, Phd
Christos holds a PhD in AI & Bioinformatics from National Technical University of Athens and has extensive experience in creating and managing R&D projects and consortia. Christos joined Protavio in 2021 as a Research & Innovation manager. Since 2023, he holds the position of Chief Innovation Officer to drive new innovative projects using proteomics.